These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38762640)

  • 1. Neoadjuvant Chemotherapy Does Not Improve Survival in cT2N0M0 Gastric Adenocarcinoma Patients: A Multicenter Propensity Score Analysis.
    Abboretti F; Lambert C; Schäfer M; Pereira B; Le Roy B; Mège D; Piessen G; Gagnière J; Gronnier C; Mantziari S; ;
    Ann Surg Oncol; 2024 Aug; 31(8):5273-5282. PubMed ID: 38762640
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Utilization and survival outcomes of neoadjuvant chemotherapy for early-stage gastric cancer.
    Janczewski LM; Buchheit J; Jacobs RC; Vitello D; Wells A; Abad J; Bentrem DJ; Chawla A
    J Surg Oncol; 2024 Aug; 130(2):249-256. PubMed ID: 38884323
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Therapy for Gastric Adenocarcinoma is Protective for Poor Oncologic Outcomes in Patients with Complications After Gastrectomy.
    Vicente D; Ikoma N; Chiang YJ; Fournier K; Tzeng CD; Song S; Mansfield P; Ajani J; Badgwell BD
    Ann Surg Oncol; 2018 Sep; 25(9):2720-2730. PubMed ID: 29987602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of neoadjuvant chemotherapy with PELF-protocoll versus surgery alone in the treatment of advanced gastric carcinoma.
    Ruf C; Thomusch O; Goos M; Makowiec F; Illerhaus G; Ruf G
    BMC Surg; 2014 Jan; 14():5. PubMed ID: 24461063
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant chemotherapy
    Li Y; Ma FH; Xue LY; Tian YT
    World J Gastroenterol; 2020 Feb; 26(8):818-827. PubMed ID: 32148379
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Safety and effectiveness of oxaliplatin combined with capecitabine or oxaliplatin combined with S-1 neoadjuvant chemotherapy in the treatment of advanced gastric cancer].
    Xie BW; Zang L; Ma JJ; Sun J; Yang X; Wang ML; Lu AG; Hu WG; Zheng MH
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):138-144. PubMed ID: 33508919
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of ypT, ypN, and Adjuvant Therapy on Survival in Gastric Cancer Patients Treated with Perioperative Chemotherapy and Radical Surgery.
    Coimbra FJF; de Jesus VHF; Ribeiro HSC; Diniz AL; de Godoy AL; de Farias IC; Felismino T; Mello CAL; Almeida MF; Begnami MDFS; Dias-Neto E; Riechelmann RSP; da Costa WL
    Ann Surg Oncol; 2019 Oct; 26(11):3618-3626. PubMed ID: 31222685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant chemotherapy is an additional option for locally advanced gastric cancer after radical gastrectomy with D2 lymphadenectomy: a retrospective control study.
    Chen L; Zhang C; Yao Z; Cui M; Xing J; Yang H; Zhang N; Liu M; Xu K; Tan F; Li Y; Jiang B; Su X
    BMC Cancer; 2021 Aug; 21(1):974. PubMed ID: 34461860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy, p53, carcinoembryonic antigen expression and prognosis after D2 gastrectomy for gastric adenocarcinoma.
    He MM; Zhang DS; Wang F; Wang ZQ; Luo HY; Ren C; Jin Y; Chen DL; Xu RH
    World J Gastroenterol; 2014 Jan; 20(1):264-73. PubMed ID: 24415881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of neoadjuvant chemotherapy combined with prophylactic intraperitoneal hyperthermic chemotherapy for patients diagnosed with clinical T4 gastric cancer who underwent laparoscopic radical gastrectomy: a retrospective cohort study based on propensity score matching.
    Lv CB; Tong LY; Zeng WM; Chen QX; Fang SY; Sun YQ; Cai LS
    World J Surg Oncol; 2024 Sep; 22(1):244. PubMed ID: 39256787
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor downstaging after neoadjuvant chemotherapy determines survival after surgery for gastric adenocarcinoma.
    Levenson G; Voron T; Paye F; Balladur P; Debove C; Chafai N; De Dios AG; Lefevre JH; Parc Y
    Surgery; 2021 Dec; 170(6):1711-1717. PubMed ID: 34561115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A multi-center retrospective study of perioperative chemotherapy for gastric cancer based on real-world data].
    Ding XW; Zheng ZC; Zhao Q; Zhai G; Liang H; Wu X; Zhu ZG; Wang HJ; He QS; He XL; Du YA; Chen LC; Hua YW; Huang CM; Xue YW; Zhou Y; Zhou YB; Wu D; Fang XD; Dai YG; Zhang HW; Cao JQ; Li LP; Chai J; Tao KX; Li GL; Jie ZG; Ge J; Xu ZF; Zhang WB; Li QY; Zhao P; Ma ZQ; Yan ZL; Zheng GL; Yan Y; Tang XL; Zhou X
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 May; 24(5):403-412. PubMed ID: 34000769
    [No Abstract]   [Full Text] [Related]  

  • 13. PRODIGY: A Phase III Study of Neoadjuvant Docetaxel, Oxaliplatin, and S-1 Plus Surgery and Adjuvant S-1 Versus Surgery and Adjuvant S-1 for Resectable Advanced Gastric Cancer.
    Kang YK; Yook JH; Park YK; Lee JS; Kim YW; Kim JY; Ryu MH; Rha SY; Chung IJ; Kim IH; Oh SC; Park YS; Son T; Jung MR; Heo MH; Kim HK; Park C; Yoo CH; Choi JH; Zang DY; Jang YJ; Sul JY; Kim JG; Kim BS; Beom SH; Cho SH; Ryu SW; Kook MC; Ryoo BY; Kim HK; Yoo MW; Lee NS; Lee SH; Kim G; Lee Y; Lee JH; Noh SH
    J Clin Oncol; 2021 Sep; 39(26):2903-2913. PubMed ID: 34133211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival benefit of conversion surgery after intensive chemotherapy for unresectable metastatic gastric cancer: a propensity score-matching analysis.
    Ohnuma H; Sato Y; Onoyama N; Hamaguchi K; Hayasaka N; Sato M; Murase K; Takada K; Miyanishi K; Murakami T; Ito T; Nobuoka T; Takemasa I; Kato J
    J Cancer Res Clin Oncol; 2021 Aug; 147(8):2385-2396. PubMed ID: 33534051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Safety and efficacy of adjuvant chemotherapy with oxaliplatin and S-1 for patients with locally advanced gastric cancer after D2 lymph nodes dissection].
    Bao YD; Zhang H; Dong L; Jiang KW; Ye YJ; Wang S; Zhou J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):145-152. PubMed ID: 33508920
    [No Abstract]   [Full Text] [Related]  

  • 16. Prognostic value of tumor regression grade (TRG) after oncological gastrectomy for gastric cancer.
    Abboretti F; Mantziari S; Didisheim L; Schäfer M; Teixeira Farinha H
    Langenbecks Arch Surg; 2024 Jun; 409(1):199. PubMed ID: 38935163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy.
    Song Y; Hirata Y; Ajani JA; Blum Murphy M; Li JJ; Das P; Minsky BD; Mansfield PF; Ikoma N; Badgwell BD
    Ann Surg Oncol; 2024 Oct; 31(10):6918-6930. PubMed ID: 39048909
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
    Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
    Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Neoadjuvant chemoradiotherapy combined with surgery versus direct surgery in the treatment of Siewert type II and III adenocarcinomas of the esophagogastric junction: long-term prognostic analysis of a prospective randomized controlled trial].
    Tian Y; Wang Q; Wang J; Qiao XY; Zhang J; Lin YC; Li Y; Fan LQ; Yang PG; Zhao Q
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):128-137. PubMed ID: 33508918
    [No Abstract]   [Full Text] [Related]  

  • 20. Association Between Waiting Time from Diagnosis to Treatment and Survival in Patients with Curable Gastric Cancer: A Population-Based Study in the Netherlands.
    Brenkman HJF; Visser E; van Rossum PSN; Siesling S; van Hillegersberg R; Ruurda JP
    Ann Surg Oncol; 2017 Jul; 24(7):1761-1769. PubMed ID: 28353020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.